Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC3114 in healthy adults
NCT03357263Phase 1Completed
- Sponsor
- GC Biopharma
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of High-dose quadrivalent influenza vaccine in influenza (2 arms), sponsored by GC Biopharma. Primary endpoint: Adverse Event at 7 days. Started Nov 2017; status: completed.
02
Drugs
High-dose quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03357263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357263.